AI drug discovery pipeline now spans small molecules and nanobodies in lab tests
const_reborn · x · 2026-07-29
The post says the team has now built three incentive mechanisms that can continuously discover both small molecules and nanobodies programmatically around the clock.
It also says those outputs are now being synthesized, produced, and tested in labs, which moves the project from virtual discovery into experimental validation. The quoted NOVA update adds that:
- nanobody production has started with Yalotein
- the nanobody track is now in experimental validation
- NOVA now has two therapeutic modalities progressing through both virtual screening and lab validation
- the platform is positioned as a multi-modality discovery engine rather than a single-target system
More from Research
- cnsplots brings publication-ready scientific plots to Python with minimal code — KevinKaichuang · 2026-07-29
- PostTrainBench v1.1 flags 234 contaminated runs and resets the leaderboard — karinanguyen · 2026-07-29
- Flowchart says LLM judges need at least 15 labels and IRR around 0.40 — IanArawjo · 2026-07-29
- AI research is splitting between one RTX 3090 and NVL72-scale clusters — _xjdr · 2026-07-29
- GenomeLayer says a genomics agent can now iterate DNA sequences toward a target — julia_kiseleva · 2026-07-29
- Natolambert’s RL course lecture maps KL regularization to better generalization than SFT — natolambert · 2026-07-29